Literature DB >> 6889515

In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma.

M D'Incalci, E Erba, M Vaghi, L Morasca.   

Abstract

VP 16 activity was investigated on cells derived from primary tumor or metastases of Lewis lung carcinoma grown in vitro. After 24 hr exposure to VP 16 we found a marginal effect at 0.1 microgram/ml, but at 1 and 10 microgram/ml [3H]-TdR uptake was 37 and 85% less than controls for primary tumor and 43 and 83% for metastases; cell numbers dropped to 41 and 76% of controls for primary tumor and 30 and 68% for metastases. After 72 hr exposure VP 16 had a similar effect on cells of primary tumor or metastases, but a cytotoxic effect was already evident at 0.01 microgram/ml and increased proportionally to the concentration reaching virtual complete cell killing at 1 microgram/ml. This study suggests that the much greater in vivo sensitivity to VP 16 of metastases than primary tumor of Lewis lung carcinoma probably arises less from an intrinsically greater susceptibility of metastatic cells than from pharmacokinetic factors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889515     DOI: 10.1016/0277-5379(82)90009-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  11 in total

1.  Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.

Authors:  F Figoli; M L Zanette; U Tirelli; R Sorio; C Lestuzzi; R Urso; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.

Authors:  M Bontenbal; A S Planting; J Verweij; R de Wit; W H Kruit; G Stoter; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 4.  Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues.

Authors:  J D Hainsworth
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide.

Authors:  J M Jones; E A Olman; M J Egorin; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Pharmacokinetics of VP16-213 given by different administration methods.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 7.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.

Authors:  C J Brindley; R B Pedley; P Antoniw; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.

Authors:  E Erba; P Ubezio; T Colombo; M Broggini; L Torti; M Vaghi; M D'Incalci; L Morasca
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 10.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.